ARPA-H Funds $28.6 Million AI Protein Research Project
Oct 12, 2026
Biotech
ARTHEx Biotech Secures $87M to Advance RNA Medicines
Sep 17, 2025
ARTHEx Biotech has successfully closed an upsized Series B financing round, raising $87 million to advance its lead program ATX-01 for Myotonic Dystrophy Type 1.
ARTHEx Biotech has successfully closed an upsized Series B financing round, raising $87 million, announced in a press release. The funding was led by new investor Bpifrance, with participation from existing shareholders such as AdBio Partners and Columbus Venture Partners.
The proceeds will be used to further the global clinical development of ARTHEx's lead program, ATX-01, which targets Myotonic Dystrophy Type 1 (DM1). ATX-01 is an anti-miR oligonucleotide designed to inhibit microRNA23b (miR-23b), a natural repressor of MBNL protein expression. This mechanism aims to increase MBNL production, decrease toxic DMPK mRNA, and improve splicing abnormalities in DM1 patients.
The financing will support the ongoing interventional Phase I/IIa ArthemiRTM study and prepare for an open-label extension to support a registrational study, further advancing ARTHEx's pipeline of targeted RNA medicines.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like AI Funding Brief, Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Funding
Oct 16 RapidCanvas Raises $29 Million to Expand Enterprise AI Platform Oct 16 KBRA Rated Anthropic BB+ Before $35 Billion Chip Financing Oct 16 Goodweek Raises $12 Million for AI Management Platform Oct 16 Intuit Agrees to Acquire AI Billing Startup Sequence for Reported $200 Million Oct 16 Matters Raises $5 Million to Build AI Consumer BankMore from Life Sciences
Oct 16 Study Tests Smartphone AI for Children's Lung Sounds Oct 16 Manhattan Physician Invests in RunPractice Oct 16 Attilio appoints Buck Institute CEO Eric Verdin as cochairman Oct 16 Aignostics launches HETA Clinical for pathology workflows Oct 16 Specialty1 Partners Invests in AI for Dental Practice OperationsFree newsletter
Life AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Whitepaper
Tensordyne Napier: What If One Rack Could Do the Work of Nine?
Tensordyne
This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.
Read moreYou may also like
XtalPi Advances Hair Loss Drug Into IND Enabling Studies
Oct 05, 2026
Biotech
Basecamp Research Raises $140 Million for AI Designed Therapeutics
Sep 24, 2026
Funding
Axya Raises C$17 Million for AI Procurement Platform
Sep 24, 2026
Funding
Phylo Launches Target Atlas for Drug Target Prioritization
Sep 29, 2026
Biotech
XtalPi Launches Kodexia siRNA Discovery Platform
Oct 06, 2026
Biotech
Free, six days a week
Daily AI Brief: the AI news that matters, in your inbox.